rs2243250 — IL4 IL4 -589C>T

Promoter polymorphism 589 bases upstream of the IL-4 transcription start site; the T allele enhances NFAT-1 binding, elevates IL-4 transcription, raises serum IgE, and amplifies Th2-skewed immune responses underlying allergic asthma, atopic dermatitis, and allergic rhinitis

See your personal result for IL4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL4 -589C>T — The Promoter Switch That Tilts the Immune System Toward Allergy

Your immune system must balance two broad modes of response: the Th1 mode, geared toward intracellular pathogens and inflammatory control, and the Th2 mode, oriented toward parasite defence, wound healing, and — in the modern environment — allergic reactions. The cytokine interleukin-4 (IL-4) is the master regulator of this Th2 arm. It drives naïve T cells toward Th2 differentiation, stimulates B cells to switch antibody production to IgE, and amplifies mast cell and eosinophil activity. The rs2243250 variant11 rs2243250 variant
A single-letter DNA change 589 bases upstream of where IL4 gene transcription begins sits at a critical regulatory position in the IL4 promoter, and it is one of the best-studied immune polymorphisms in the allergy and asthma literature.

The Mechanism

The -589 position in the IL4 promoter falls within an inverted palindromic sequence (bases −603 to −588) that forms part of a binding site for NFAT-122 NFAT-1
Nuclear Factor of Activated T cells — a transcription factor that enters the nucleus when T cells are stimulated and drives expression of cytokine genes. The C allele (reference) has lower affinity for NFAT-1 homodimers; the T allele subtly alters the palindrome geometry, increasing dimer binding affinity. The result is higher basal and stimulated IL-4 transcription in T carriers, leading to elevated serum IL-4 protein and downstream elevation of total serum IgE. This is not a dramatic loss-of-function change — it is a quantitative shift in the regulatory rheostat, which explains why the associations are probabilistic and population-level rather than deterministic.

The Evidence

The strongest evidence comes from a 2020 meta-analysis of 55 case-control studies33 2020 meta-analysis of 55 case-control studies
Kousha et al., BMC Immunology 2020 — 9,572 asthma cases and 9,881 controls across 49 publications covering 9,572 asthma cases and 9,881 controls. The T allele increased asthma risk across all genetic models tested: dominant model OR 1.22, recessive OR 1.17, and allelic OR 1.21. Subgroup analyses confirmed significance in both pediatric and adult cohorts and across Asian, American, and European populations, making this one of the most replicated allergy-related promoter polymorphisms in the literature.

For allergic rhinitis, a 2021 meta-analysis of 9 studies44 2021 meta-analysis of 9 studies
Jiang & Yan, Bioscience Reports 2021 — 1,709 allergic rhinitis patients found that TT homozygotes carried a 56% higher rhinitis risk compared to CC homozygotes (OR 1.56, 95% CI 1.13–2.17), with the allele model giving OR 1.19 (95% CI 1.04–1.35).

The IgE connection was directly quantified in a study of 500 asthmatic children55 study of 500 asthmatic children
Li et al., Annals of Allergy, Asthma & Immunology 2014: children carrying multiple Th2-pathway risk alleles including rs2243250 showed mean IgE levels up to 902 KU/L compared to 71 KU/L in those with no risk alleles. A Filipino case-control study found the TT genotype specifically was associated with very high IgE (>1,000 IU/mL), OR 3.97 (p=0.016).

Evidence for atopic dermatitis is moderate — several studies show T allele enrichment in AD patients but effect sizes are smaller and replication is less consistent than for asthma. The Th2 mechanism is clearly relevant (IL-4 drives skin barrier disruption and IgE sensitization in AD), but the promoter SNP explains only a fraction of the genetic variance.

Practical Actions

For T carriers, the elevated Th2 tone means: (1) total serum IgE is a meaningful biomarker to track if allergic symptoms develop; (2) strategies that moderate Th2 skewing — such as quercetin supplementation, which demonstrably suppresses IL-4 transcription in activated T cells — have mechanistic relevance beyond generic anti-inflammatory advice; (3) allergen exposure management is especially worthwhile because this variant amplifies the IgE-sensitization response to initial exposures.

Interactions

This promoter variant operates in the same Th2 signalling axis as rs1801275 in IL4R (the IL-4 receptor alpha chain) and rs20541 in IL13 (interleukin-13, which shares the IL4Rα/IL-2Rγ receptor complex and has overlapping biological functions). Carriers of risk alleles at multiple loci in this pathway show multiplicative elevation of IgE and additive risk for asthma in gene-gene interaction studies. A four-locus model including rs2243250, IL13 rs20541, FCER1B, and ADRB2 demonstrates synergistic asthma susceptibility in Han Chinese children. rs2070874 (IL4 -33C/T), the second common IL4 promoter SNP, is in strong linkage disequilibrium with rs2243250 and should be considered in haplotype analyses — the CC haplotype at both sites is associated with inflammatory bowel disease risk while the TT haplotype tracks with atopic disease.

Genotype Interpretations

What each possible genotype means for this variant.

CC Balanced Th2 Tone Normal

Standard IL-4 promoter activity and typical IgE regulation

The CC genotype confers the population-typical Th2 tone. IL-4 transcription responds to immunological stimuli normally, without the gain-of-function effect conferred by the T allele. Your baseline serum IgE and Th1/Th2 balance are not genetically disadvantaged at this locus, though environmental factors (early allergen exposure, microbiome composition, pollution) still play a major role in atopic disease susceptibility. You may still develop allergies, asthma, or atopic dermatitis — this SNP is one of many contributing factors — but your IL4 promoter is not adding genetic amplification to that risk.

CT Elevated Th2 Tone Intermediate

One T allele raises IL-4 expression and IgE levels modestly

The single T allele creates a heterodimer situation at the palindromic NFAT-1 site: one chromosome has enhanced NFAT-1 binding, the other does not. The net effect is an intermediate elevation in IL-4 output — higher than CC, but not as pronounced as TT. In practical terms this means: if you develop allergic symptoms, your Th2 axis is biologically primed to escalate the response; serum IgE may trend higher than average; and early allergen sensitization events may be more likely to become persistent IgE-mediated reactions. The association with asthma is established at population scale across multiple meta-analyses spanning European, Asian, and American cohorts, though individual risk depends heavily on environmental co-exposures.

TT High Th2 Tone High Risk

Two T alleles substantially amplify IL-4 output, IgE production, and Th2 polarization

With two T alleles, both copies of the IL4 promoter carry the enhanced NFAT-1 binding palindrome. IL-4 is constitutively more active in response to T cell stimulation. The consequences cascade through the Th2 axis: (1) naïve T cells are more efficiently polarized toward Th2 phenotype; (2) B cells receive stronger IL-4 class-switching signals, elevating total and allergen-specific IgE; (3) mast cell and eosinophil survival is enhanced; (4) IFN-γ production (the Th1 counterbalance) is indirectly suppressed. In infectious contexts, the same Th2 amplification that drives allergy can impair Th1-dependent pathogen clearance — a meta-analysis of tuberculosis susceptibility found TT homozygotes may have modestly elevated TB risk under a recessive model in European populations, consistent with the Th2/Th1 trade-off. For TT carriers, proactive IgE monitoring, avoidance of known sensitizing environments during high-risk periods, and targeted Th2-modulating supplementation have the strongest genotype-specific rationale.